Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Effectiveness of opioid agonist treatments for opioid use disorder

FY 2022-23

Summary
In 2021, 7,560 people died from opioid-related overdoses in Canada, with synthetic opioids, such as fentanyl, involved in 86% of the deaths. Previous studies have found that when clients with opioid use disorder (OUD) take opioid agonist treatments (OATs), such as buprenorphine and methadone, they have lower rates of overdose and death. However, these studies were completed before fentanyl became widely used and had other limitations. Additionally, there are no personalized estimates of treatment effectiveness to help clients select between OATs. There is also limited information to guide clients interested in stopping OATs after long-term use (at least 3 years). This set of projects will address important limits in our understanding of how to provide optimal treatments for people with OUD. In the first project, we will assess whether use of OAT was associated with reduced overdoses, deaths, and emergency room visits during a period when fentanyl was widely used. Next, we will determine the relative effectiveness of methadone, buprenorphine, and newer OATs during this time. This will be the largest study assessing the relative effectiveness of OATs during the fentanyl era and will address limitations of previous studies. In the second project, we will create a model that will allow clinicians to estimate the chance that a client continues an OAT for 12 weeks, based on client risk factors. Taking OAT continuously for 12 weeks is associated with a number of positive outcomes, including decreased overdose risk and improved quality of life. This information will allow clients to select the best OAT for their situation. In the third project, we will assess whether individuals stopping OAT after at least 3 years of use have increased rates of overdoses, death, and visiting emergency rooms compared with individuals who continue taking OAT. This will provide valuable information to clients deciding whether to continue OAT after a long period of use.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
475562
Name
Kleinman Robert A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Doctoral Research Awards - B
Projecttitle
Effectiveness of opioid agonist treatments for opioid use disorder
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Buprenorphine; Epidemiology; Methadone; Mortality; Opioid Agonist Treatment; Opioid Use Disoorder; Overdose; Treatment Effectiveness
Abstract
In 2021, 7,560 people died from opioid-related overdoses in Canada, with synthetic opioids, such as fentanyl, involved in 86% of the deaths. Previous studies have found that when clients with opioid use disorder (OUD) take opioid agonist treatments (OATs), such as buprenorphine and methadone, they have lower rates of overdose and death. However, these studies were completed before fentanyl became widely used and had other limitations. Additionally, there are no personalized estimates of treatment effectiveness to help clients select between OATs. There is also limited information to guide clients interested in stopping OATs after long-term use (at least 3 years). This set of projects will address important limits in our understanding of how to provide optimal treatments for people with OUD. In the first project, we will assess whether use of OAT was associated with reduced overdoses, deaths, and emergency room visits during a period when fentanyl was widely used. Next, we will determine the relative effectiveness of methadone, buprenorphine, and newer OATs during this time. This will be the largest study assessing the relative effectiveness of OATs during the fentanyl era and will address limitations of previous studies. In the second project, we will create a model that will allow clinicians to estimate the chance that a client continues an OAT for 12 weeks, based on client risk factors. Taking OAT continuously for 12 weeks is associated with a number of positive outcomes, including decreased overdose risk and improved quality of life. This information will allow clients to select the best OAT for their situation. In the third project, we will assess whether individuals stopping OAT after at least 3 years of use have increased rates of overdoses, death, and visiting emergency rooms compared with individuals who continue taking OAT. This will provide valuable information to clients deciding whether to continue OAT after a long period of use.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kleinman, Robert A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~